Acalabrutinib + R-CHOP standard of care + Acalabrutinib combination with Rituximab + Acalabrutinib monotherapy
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mantle-cell Lymphoma
Conditions
Mantle-cell Lymphoma
Trial Timeline
Sep 5, 2025 → Dec 15, 2028
NCT ID
NCT07029737About Acalabrutinib + R-CHOP standard of care + Acalabrutinib combination with Rituximab + Acalabrutinib monotherapy
Acalabrutinib + R-CHOP standard of care + Acalabrutinib combination with Rituximab + Acalabrutinib monotherapy is a phase 2 stage product being developed by AstraZeneca for Mantle-cell Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07029737. Target conditions include Mantle-cell Lymphoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07029737 | Phase 2 | Recruiting |
Competing Products
9 competing products in Mantle-cell Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| enzastaurin | Eli Lilly | Phase 2 | 52 |
| Pirtobrutinib + Ibrutinib + Acalabrutinib + Zanubrutinib | Eli Lilly | Phase 3 | 77 |
| Venetoclax | AbbVie | Phase 2 | 52 |
| ABT-199 and Ibrutinib Combination | AbbVie | Phase 1 | 33 |
| SCH 727965 + Bortezomib + Alemtuzumab | Merck | Phase 2 | 52 |
| Obinutuzumab + Glofitamab + Venetoclax Oral Product + Zanubrutinib Oral Capsule | Roche | Phase 2 | 52 |
| PD-0332991 | Pfizer | Phase 1 | 32 |
| Copanlisib (BAY80-6946) | Bayer | Phase 2 | 49 |
| Yttrium-ibritumomab (Zevalin) + Rituximab | Biogen | Phase 2 | 49 |